Skip to content
Medxy AI
  • Wellness & Lifestyle
  • Clinical Updates
  • Medical News
  • Wellness & Lifestyle
  • Clinical Updates
  • Medical News
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • cabozantinib
Cabozantinib Plus Atezolizumab in mCRPC: CONTACT-02 Phase 3 Final Results and Clinical Implications
Posted inClinical Updates Wellness & Lifestyle

Cabozantinib Plus Atezolizumab in mCRPC: CONTACT-02 Phase 3 Final Results and Clinical Implications

Posted by By MedXY 08/02/2025
The CONTACT-02 phase 3 trial shows cabozantinib plus atezolizumab improves progression-free survival but not overall survival in advanced mCRPC post-ARPI, offering a novel non-androgen receptor-based option.
Read More
  • Elevated D-Dimer Levels: Beyond Pulmonary Embolism—Uncommon Conditions Many Doctors Overlook
  • Understanding and Managing Alzheimer’s Disease: A Comprehensive Guide
  • Understanding and Managing Seasonal Allergies: A Comprehensive Guide
  • Understanding and Managing Hypertension: A Comprehensive Guide
  • Understanding and Managing Chronic Fatigue Syndrome
  • About us
  • Contact us
  • Privacy Policy
  • Subscribe Now!
  • English
  • 日本語
  • Tiếng Việt
  • 中文

aging Alzheimer's disease Antibiotics breast cancer cardiovascular health clinical trial clinical trials diabetes diagnosis diet epidemiology exercise FDA FDA approval health healthcare HIV Hypertension immunotherapy longevity maternal health men's health Menopause mental health multiple myeloma nutrition obesity PCOS Pediatrics phase 3 trial Physical Activity Pregnancy prevention public health randomized trial semaglutide sexual health sleep treatment type 2 diabetes Vaccine walking weight loss wellness women's health

Your health, we care

Copyright 2025 — Medxy AI. All rights reserved.
Scroll to Top